IP Library Granted Patent US 7,534,435
Granted Patent B2
US 7,534,435 · App. 11/411,294 · Granted May 19, 2009

Glycosylated specificity exchangers

Assignee: Tripep AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,534,435
App. No.
11/411,294
Granted
May 19, 2009
Kind
B2
Abstract

The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.

Claims (12)

1. An isolated glycoconjugate peptide joined to a support, wherein said glycoconjugate peptide comprises an HIV gp120 binding fragment of CD4 less than 20 amino acids in length synthetically conjugated to gal α (1,3) gal β.

2. The glycoconjugate peptide of claim 1 , wherein the sequence of said fragment is selected from the group consisting of SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5. SEQ. ID. NO. 6, SEQ. ID. NO. 7, SEQ. ID. NO. 8, and SEQ. ID. NO. 9.

3. The isolated glycoconjugate peptide of claim 1 , wherein said glycoconjugate peptide is linear.

4. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to said HIV gp120 binding fragment of CD4 by attachment at one amino acid.

5. The isolated glycoconjugate peptide of claim 4 , wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.

6. The isolated glycoconjugate peptide of claim 4 , wherein said gal α (1,3) gal β is synthetically conjugated by an NH 2 -linkage.

7. The isolated glycoconjugate peptide of claim 4 , wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of the HIV gp120 binding fragment of CD4.

8. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.

9. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated by an NH 2 -linkage.

10. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of the HIV gp120 binding fragment of CD4.

11. The isolated glycoconjugate peptide of claim 1 , wherein said support is plastic.

12. The isolated glycoconjugate peptide of claim 1 , wherein said support is a microtiter plate.

Assignments (4)
SECURITY INTEREST Recorded Sep 29, 2015
From: TRIPEP AB
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 036714/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2014
From: CHRONTECH PHARMA AB
To: TRIPEP AB
Reel/Frame 034521/0261 →
CHANGE OF NAME Recorded Apr 14, 2010
From: TRIPEP AB
To: CHRONTECH PHARMA AB
Reel/Frame 024233/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2007
From: SALLBERG, MATTI; VAHLNE, ANDERS; PERDOMO, MARIA
To: TRIPEP AB
Reel/Frame 020108/0618 →
Continuity (4)
Continuation 1091375400 · Aug 6, 2004
Continuation In Part 1077362800 · Feb 5, 2004
Provisional Application 6044617200 · Feb 6, 2003
Related Publication 20060194247A1 · Aug 31, 2006